Semax vs Adamax
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: SEMAX, Heptapeptide SEMAX
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.
Also: Semax derivative
Adamax is sold widely as an enhanced Semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. Vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. This page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Semax has stronger research evidence (Human Trials) compared to Adamax (Preclinical).
Detailed Comparison
| Attribute | Semax | Adamax |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is derived from ACTH(4-10) but, unlike ACTH, does not stimulate the adrenal or cortisol axis; its main documented action is upregulating brain-derived neurotrophic factor (BDNF) and its receptor TrkB, especially in the hippocampus. In rats, a single dose increases BDNF protein and mRNA and raises TrkB phosphorylation, activating growth and survival pathways (such as MAPK/ERK and PI3K/Akt) that support neuron health and plasticity. It also modulates dopamine and serotonin signaling and influences genes tied to the immune and vascular response after brain ischemia. The combined effect in animal models is neuroprotection against insults like reduced blood flow and oxidative stress, plus enhanced learning and memory. The Pro-Gly-Pro extension makes it more stable than the bare ACTH(4-10) sequence, which is partly why it stays active intranasally. | What is claimed is that Adamax is a structurally modified Semax analog, with modifications intended to improve stability and blood-brain barrier penetration relative to Semax itself. Semax is a synthetic fragment of ACTH (4-10) developed in Russia, and its best-supported mechanism is upregulation of BDNF and NGF in the hippocampus and cortex, alongside modulation of the monoamine systems and some effect on the melanocortin pathway. If Adamax is what it is sold as, its mechanism should be broadly that of Semax with altered pharmacokinetics. That is a reasonable inference and it is not the same thing as a demonstrated mechanism. No published pharmacology characterises Adamax specifically. |
| Common Dosing | 200-600 mcg intranasal daily 1-3x daily, intranasal | 100-300 mcg daily (intranasal) Once daily, morning |
| Administration | Intranasal spray (most common) | Intranasal is the most commonly reported route, following Semax practice. Subcutaneous is also reported. |
| Typical Duration | 10-30 days typical | Community protocols typically report 2-4 week blocks rather than continuous use |
| Best Time to Take | Morning or early afternoon | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The mechanistic core is well documented preclinically: Dolotov et al. (2006, Brain Research) showed a single intranasal Semax dose raised hippocampal BDNF protein, TrkB phosphorylation, and BDNF and TrkB mRNA in rats, alongside improved learned behavior. Additional rat work shows neuroprotection and changes in immune- and vascular-related gene expression after experimental stroke. Human clinical use is real but the published trials are mostly Russian-language, small, and frequently non-randomized or open-label: studies in acute ischemic-stroke patients reported faster recovery of neurological function, and a 2018 study reported increased plasma BDNF with improvements on disability and motor scales. These results are promising but methodologically weaker than Western regulatory-grade trials and have not been replicated in large independent Western studies. Honest summary: solid animal mechanistic data and decades of Russian clinical use, but the human cognitive and stroke claims rest on small, mostly non-randomized studies and are not validated by FDA or EMA-grade trials. | There is no peer-reviewed clinical or preclinical literature on Adamax under that name that stands up to a search. What exists is a substantial Russian-language research base on Semax, its parent, which includes clinical use in Russia for stroke recovery, cognitive impairment and optic nerve conditions, and which supports the BDNF and NGF mechanism. Extending that evidence to Adamax requires assuming the analog behaves like the parent, and no published work confirms that assumption. Everything circulating about Adamax's potency relative to Semax is vendor claim and user report, not measurement. The honest position is that this is an uncharacterized research compound whose parent has real but largely non-Western evidence behind it. If you want the compound with actual literature, that compound is Semax. |
Frequently Asked Questions: Semax vs Adamax
What is the difference between Semax and Adamax?
Semax is a cognitive peptide that semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) developed in russia in the 1980s as an analog of the acth(4-10) fragment, with a pro-gly-pro tail added to resist breakdown. it is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the acth fragment without the parent hormone's cortisol-raising activity. it is used clinically and registered in russia (including for ischemic stroke and cognitive disorders) but is not approved by the fda or ema, and western evidence is limited. Adamax is a cognitive peptide that adamax is sold widely as an enhanced semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. this page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semax or Adamax?
Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while Adamax is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semax and Adamax be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and Adamax together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.